Insulet (NASDAQ:PODD) Stock Price Up 4.9% – Here’s Why

Insulet Corporation (NASDAQ:PODD) was up 4.9% during trading on Tuesday . The stock traded as high as $145.87 and last traded at $146.5610. 92,700 shares were traded during mid-day trading, a decline of 93% from the average session volume of 1,310,668 shares. The stock had previously closed at $139.70.

Insulet News Summary

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s recent operating performance provides a counterpoint to the legal concerns: the company’s latest reported quarter exceeded analyst expectations for both earnings and revenue, with revenue up 23.5% year over year. This may be supporting investor confidence.
• Neutral Sentiment: Multiple firms, including Glancy Prongay Wolke & Rotter, Robbins LLP, Rosen Law Firm, Portnoy Law Firm, and others, are soliciting investors who purchased Insulet securities between February 21, 2025, and May 26, 2026. The firms cite a federal securities class action and an August 31, 2026 deadline for investors to seek appointment as lead plaintiff. Deadline Alert: Insulet Corporation Shareholders
• Negative Sentiment: The complaints allege that Insulet made materially false or misleading statements about manufacturing controls and the safety and reliability of its Omnipod insulin-delivery products. The allegations reportedly center on two voluntary medical-device corrections and claims that broader manufacturing defects were not adequately disclosed. The allegations have not been proven in court. Insulet Corporation Stockholders Class Action
• Negative Sentiment: One law-firm notice says investor confidence deteriorated after the Omnipod corrections and attributes an approximately $90-per-share decline to the alleged disclosures. If the litigation produces further recalls, regulatory action, settlements, or evidence of persistent quality problems, Insulet could face higher costs and slower growth. PODD Deadline Alert from Levi & Korsinsky

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on PODD shares. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Insulet in a research note on Tuesday, June 23rd. They set a “buy” rating and a $190.00 price objective for the company. Citigroup lifted their target price on shares of Insulet from $165.00 to $172.00 and gave the company a “neutral” rating in a report on Wednesday, July 8th. Evercore set a $180.00 price target on shares of Insulet in a research report on Monday, July 6th. Sanford C. Bernstein lowered their price target on Insulet from $200.00 to $175.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Finally, Oppenheimer lowered Insulet from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 5th. Fourteen equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Insulet has a consensus rating of “Hold” and a consensus target price of $195.40.

Insulet Price Performance

The business’s 50 day moving average price is $154.75 and its 200-day moving average price is $185.83. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65. The company has a market cap of $10.51 billion, a PE ratio of 28.32, a price-to-earnings-growth ratio of 1.17 and a beta of 1.10.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.19. The business had revenue of $801.70 million during the quarter, compared to the consensus estimate of $787.39 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The business’s quarterly revenue was up 23.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, analysts forecast that Insulet Corporation will post 6.51 earnings per share for the current year.

Insiders Place Their Bets

In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of the stock in a transaction dated Wednesday, June 3rd. The stock was bought at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the purchase, the director directly owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. The trade was a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.36% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Larson Financial Group LLC grew its stake in Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 47 shares in the last quarter. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Insulet in the 4th quarter valued at approximately $26,000. DV Equities LLC acquired a new position in shares of Insulet in the 4th quarter valued at approximately $28,000. Elyxium Wealth LLC purchased a new position in shares of Insulet during the 4th quarter valued at approximately $28,000. Finally, Mcguire Capital Advisors Inc. purchased a new position in shares of Insulet during the 4th quarter valued at approximately $29,000.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.